Yahoo Finance

(Bloomberg) -- Moderna Inc. was awarded an additional $590 million from the US government to help the company develop a vaccine aimed at protecting people from bird flu.

Most Read from Bloomberg

• These Homes Withstood the LA Fires. Architects Explain Why

• NYC Commuters Get New Way to Dodge Traffic: $95 Helicopter Rides

• Scaramucci, Ackman Donate to Whitney Tilson’s NYC Mayoral Run

• In a City of Sprawl, Wildfire Evacuation Is Getting Harder

• Will Americans Ever Lose Their Taste for Telework?

The funding will support late-stage development and licensing of pre-pandemic vaccines and expansion of human studies for up to five additional subtypes of pandemic influenza, according to a statement Friday.

First discovered in 1996 in geese bred in southern China, the H5N1 strain has caused hundreds deaths in people over the years, mainly via exposure to infected animals. The version of the virus spreading in North America right now has led to only a few serious cases, but concerns have been rising since a death was linked to the virus in Louisiana earlier this month.

Since 2023, Moderna has been studying a vaccine to keep people from getting infected with H5N1, which has been decimating flocks of birds throughout the nation. It has also run rampant in herds of dairy cows and occasionally spread to farm workers.

In July, the company received $176 million from the US government to speed development of the vaccine, which uses messenger RNA, the same technology that allowed quick development of Covid shots. Based on positive preliminary data, Moderna is preparing to advance the vaccine into a late-stage study.

Meanwhile, US public health officials are stepping up efforts to detect and contain the ongoing bird flu outbreak. On Thursday, officials pushed for faster bird flu testing in hospitalized patients, adding urgency to their efforts to identify human cases.

Moderna shares rose 4.2% after US markets closed. They’ve lost two-thirds of their value over the past 12 months.

The company said it plans to share results from its early-stage bird flu vaccine trial at an upcoming scientific meeting.

(Updates with background starting in third paragraph.)

Most Read from Bloomberg Businessweek

• Walgreens Replaced Fridge Doors With Smart Screens. It’s Now a $200 Million Fiasco

• The Swiss Sneaker Brand Outrunning Nike and Adidas

• Giant Batteries Are Transforming the World’s Electrical Grids

• How Long Can Toyota Put Off Figuring Out EVs?

• At Charles Schwab, a Fresh Start After a Close Call

©2025 Bloomberg L.P.